|
Mar 9
|
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
|
|
Dec 9
|
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
|
|
Dec 7
|
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
|
|
Aug 8
|
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
|